Report on a dual-action human afucosylated anti-GARP antibody that combines ADCC induction with blockade of TGF-β1 activation to boost anti-tumor immunity.
Key Takeaways
- Presage Biosciences, Inc., Seattle, WA, United States The final, formatted version of the article will be published soon
- You have multiple emails registered with Frontiers: You don't have a Frontiers account ?
- PBA-0111 was compared with clinically tested anti-GARP antibodies, including DS-1055a- and ABBV-151- like antibodies